Genocea Biosciences, Inc., a Cambridge, Mass.-based clinical-stage company advancing innovative T cell vaccines for infectious diseases, has raised $30m in a Series C financing round.
Backers include the Bill & Melinda Gates Foundation and CVF, an affiliate of Henry Crown and Company, and existing investors Polaris Venture Partners, Lux Capital, SR One, Johnson & Johnson Development Corporation, Skyline Ventures, Cycad Group, Auriga Partners, MP Healthcare Ventures and Morningside.
With the close of this financing round, Genocea, which is led by CEO Chip Clark, has raised a total of $76 million in equity financing to date.
The company intends to use the latest proceeds for the continued development of its two lead programs:
– GEN-003, a clinical-stage therapeutic vaccine candidate designed to reduce the frequency and severity of clinical outbreaks associated with moderate-to-severe Herpes Simplex Virus type 2 (HSV-2), and
GEN-004, a preclinical vaccine candidate to prevent infections caused by Streptococcus pneumoniae.
In addition, Genocea will expand its malaria program in collaboration with the Bill & Melinda Gates Foundation, using its proprietary ATLAS™ platform to profile the immune response of volunteers participating in malaria vaccine trials, to identify antigens for potential inclusion in a protein subunit vaccine.